Radiotherapy for Localized Orbital Mucosa-Associated Lymphoid Tissue LymphomaMonzen Y.a · Hasebe H.b
Departments of aRadiology and bOphthalmology, Hiroshima Prefectural Hospital, Hiroshima, Japan
Do you have an account?
- Rent for 48h to view
- Buy Cloud Access for unlimited viewing via different devices
- Synchronizing in the ReadCube Cloud
- Printing and saving restrictions apply
Rental: USD 8.50
Cloud: USD 20.00
Article / Publication Details
Fourteen patients with localized orbital mucosa-associated lymphoid tissue lymphoma diagnosed between 1998 and 2005 were reviewed. Five patients were males and 9 were females, with a mean age of 58 years. In 8 patients, the disease arose from the conjunctiva, and in 6 patients, it originated from the retrobulbar space. Patients were treated with radiotherapy alone at a dose range from 30 to 54 Gy. All patients with conjunctival lymphoma achieved complete remission (CR). Four patients with retrobulbar lymphoma obtained CR, and unconfirmed CR (CRu) was observed in 2 cases. Orbital extraconal lymphoma disappeared. However, intraconal cord-like tumor and mass involving the medial extraocular muscle remained with the absence of regrowth over the long term. There have been very few reports discussing the histology of residual mass after radiotherapy. Residual mass was suggested to be reactive lymphoid hyperplasia. As a dose of more than 40 Gy induced dry eye syndrome or cataract, the dose must not exceed 40 Gy in order to achieve safe treatment of orbital mucosa-associated lymphoid tissue lymphoma.
© 2007 S. Karger AG, Basel
- Isaacson PG, Wright DH: Malignant lymphoma of mucosa-associated lymphoid tissue. A distinctive type of B-cell lymphoma. Cancer 1983;52:1410–1416.
Jaffe ES, Harris NL, Stein H (eds): WHO Classification of Tumours. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. IARC Press, Lyon, 2001.
The American Joint Committee on Cancer: AJCC Cancer Staging Manual, ed 6. New York, Springer, 2002, pp 393–405.
WHO Handbook for Reporting Results of Cancer Treatment, WHO Offset. Publication No 48. Geneva, World Health Organization, 1979.
- Thieblemont C, Bastion Y, Berger F, Rieux C, Salles G, Dumontet C, Felman P, Coiffier B: Mucosa-associated lymphoid tissue gastrointestinal and nongastrointestinal lymphoma behavior: analysis of 108 patients. J Clin Oncol 1997;15:1624–1630.
- Thieblemont C, Berger F, Dumontet C, Moullet I, Bouafia F, Felman P, Salles G, Coiffier B: Mucosa-associated lymphoid tissue lymphoma is a disseminated disease in one third of 158 patients analyzed. Blood 2000;95:802–806.
- Tsang RW, Gospodarowicz MK, Pintilie M, Bezjak A, Wells W, Hodgson DC, Crump M: Stage I and II MALT lymphoma: results of treatment with radiotherapy. Int J Radiat Oncol Biol Phys 2001;50:1258–1264.
- Zinzani PL, Magagnoli M, Ascani S, Ricci P, Poletti V, Gherlinzoni F, Frezza G, Bendandi M, Stefanetti C, Merla E, Pileri S, Tura S: Nongastrointestinal mucosa-associated lymphoid tissue (MALT) lymphomas: clinical and therapeutic features of 24 localized patients. Ann Oncol 1997;8:883–886.
- Zinzani PL, Magagnoli M, Galieni P, Marteteli M, Poletti V, Zaja F, Molica S, Zaccaria A, Cantonetti AM, Gentilini P, Guardigni L, Ghertinzoni F, Ribersani M, Bendandi M, Albertini P, Tura S: Nongastrointestinal low-grade mucosa-associated lymphoid tissue lymphoma: analysis of 75 patients. J Clin Oncol 1999;17:1254–1258.
- Komatsu T, Kikuchi Y, Nishijima H, Takanaka T, Terayama N, Matsui O: Experience of two orbital MALT lymphomas treated with radiotherapy, and review of the literature. Radiat Med 2001;19:317–320.
- Akpek EK, Polcharoen W, Ferry JA, Foster CS: Conjunctival lymphoma masquerading as chronic conjunctivitis. Ophthalmology 1999;106:757–760.
- Galieni P, Polite E, Leccisotti A, Marotta G, Lasi S, Bigazzi C, Bucalossi A, Frezza G, Lauria F: Localized orbital lymphoma. Haematologica 1997;82:436–439.
- Hasegawa M, Kojima M, Shioya M, Tamaki Y, Saitoh J, Sakurai H, Kitamoto Y, Suzuki Y, Niebe H, Nakano T: Treatment results of radiotherapy for malignant lymphoma of the orbit and histopathologic review according to the WHO classification. Int J Radiat Oncol Biol Phys 2003;57:172–176.
- Cahill MT, Moriarty PA, Kennedy SM: Conjunctival ‘MALToma’ with systemic recurrence. Arch Ophthalmol 1998;116:97–99.
- Le QT, Eulau SM, George TI, Hildebrand R, Warnke RA, Donaldson SS, Hoppe RT: Primary radiotherapy for localized orbital MALT lymphoma. Int J Radiat Oncol Biol Phys 2002;52:657–663.
- Letschert JGJ, González G, Oskam J, Koornneef L, Dijk JDP, Boukes R, Bras J, Heerde P, Bartelink H: Results of radiotherapy in patients with stage I orbital non-Hodgkin’s lymphoma. Radiother Oncol 1991;22:36–44.
- Martinet S, Ozsahin M, Belkacēmi Y, Landmann C, Poortmans P, Oehlere C, Scandolaro L, Krengli M, Maingon P, Miralbell R, Studer G, Chauvet B, Marnitz S, Zouhair A, Mirimanoff RO: Outcome and prognostic factors in orbital lymphoma: a rare cancer network study on 90 consecutive patients treated with radiotherapy. Int J Radiat Oncol Biol Phys 2003;55:892–898.
Nguyen LN: The orbit; in Cox JD, Ang KK (eds): Radiation Oncology, ed 8. Mosby, St. Louis, 2003, pp 282–292.
Article / Publication Details
Copyright / Drug Dosage / DisclaimerCopyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.